Variables | Non-Renal-SLE n = 153 | Renal-SLE n = 43 | p |
---|---|---|---|
Age (years) a | 46 (18–73) | 43 (18–62) | 0.13 |
Disease duration, (years) a | 9 (2–28) | 6 (2–28) | 0.10 |
C3 fraction complement (mg/dL) a | 142.0 (60.0–142.0) | 154.5 (42.0–252.0) | 0.84 |
C4 fraction complement (mg/dL) a | 31 (7.4–71.7) | 31.3 (6.7–62.9) | 0.92 |
Positive anti-dsDNA b | 39 (25.5) | 16 (37.2) | 0.27 |
SLEDAI (score) a | 2 (0–12) | 6 (4–12) | < 0.001 |
Creatinine clearance (mL/min) a | 123.1 (96.6–158.3) | 114.9 (80.8–147.0) | 0.06 |
eGFR (mL/min/m2) a | 111.2 (29.6–258.9) | 108.6 (17.1–182.9) | 0.91 |
Serum creatinine (mg) a | 0.7 (0.6–2.2) | 0.7 (0.4–3.7) | 0.44 |
Immunosuppressive drugs b | 112 (73.2) | 33 (76.7) | 0.64 |
Glucocorticoid user b | 153 (100) | 43 (100) | – |
Glucocorticoid dose (mg/day) a | 7.5 (2.5–50.0) | 20 (2.5–75.0) | < 0.001 |
Immunosuppressive drugs b | 112 (73.2) | 33 (76.7) | 0.69 |
- Azathioprine users b | 73 (47.7) | 18 (41.8) | 0.88 |
- Cyclophosphamide users b | 9 (5.9) | 3 (9.3) | 0.29 |
- Mycophenolate users b | 37 (24.2) | 19 (44.2) | 0.002 |
Others drugs (Methotrexate) b | 23 (15.0) | 4 (9.3) | 0.44 |